Ignite Creation Date:
2025-12-25 @ 3:46 AM
Ignite Modification Date:
2026-01-12 @ 1:53 PM
Study NCT ID:
NCT04999202
Status:
TERMINATED
Last Update Posted:
2025-02-10
First Post:
2021-08-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults
Sponsor:
Bayer
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Solid Tumors | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Non-small cell lung cancer (NSCLC) | View |
| None | Head and neck squamous cell carcinoma (HNSCC) | View |
| None | Urothelial Cancer | View |
| None | Advanced cancer | View |
| None | Immunotherapy | View |
| None | Immuno oncology | View |
| None | Aryl Hydrocarbon Receptor inhibitor(AhRi) | View |
| None | Aryl Hydrocarbon Receptor | View |
| None | Pembrolizumab | View |
| None | aPD1 | View |
| None | Checkpoint inhibitor | View |